None
Quote | AbbVie Inc. (NYSE:ABBV)
Last: | $167.29 |
---|---|
Change Percent: | 0.08% |
Open: | $167.66 |
Close: | $167.29 |
High: | $169.29 |
Low: | $165.57 |
Volume: | 5,447,063 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | AbbVie Inc. (NYSE:ABBV)
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 11:24:05 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie Q1 Preview: Skyrizi and Rinvoq’s...
Message Board Posts | AbbVie Inc. (NYSE:ABBV)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABBV News Article - AbbVie Stock Plunged: Should You Buy the Dip? | whytestocks | investorshangout | 05/01/2023 7:35:47 PM |
$ABBV reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 12:00:28 PM |
$ABBVFDA expands Qulipta label_to prevention of chronic migraine: | DewDiligence | investorshub | 04/18/2023 6:23:32 PM |
Skyrizi phase-3 in UC hits all endpoints: | DewDiligence | investorshub | 03/23/2023 2:02:00 PM |
$ABBV advances Rinvoq to phase-3 in lupus: | DewDiligence | investorshub | 03/23/2023 2:00:38 PM |
News, Short Squeeze, Breakout and More Instantly...
Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Pha...
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study PR Newswire Upadacitinib demonstrated superiority versus dupilumab in primary...
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands PR Newswire Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX ® Cosmetic, the JUVÉDERM ® ...